Summary
| Direction in ME/CFS | ↑ Elevated — higher than in the comparison group |
|---|---|
| Category | Autoimmune |
| Also described as | GPCR autoAbs |
| Compared against | HC — LC/PACVS overlap (healthy controls; long COVID/post-acute COVID-19 vaccination syndrome overlap) |
| Associated symptoms | Dysautonomia |
| Test type | Blood test (serum / plasma / whole blood) |
| Source | Maksoud et al. 2023 — doi:10.1186/s12916-023-02893-9 |
| Condition atlas | ME/CFS Biomarker Atlas |
Other conditions where Anti-GPCR autoantibodies (panel) is reported
- Anti-GPCR autoantibodies in Long COVID — ↑ elevated vs HC
- Anti-GPCR autoantibodies (panel) in PACVS — ↑ elevated vs HC
See the cross-condition hub: Anti-GPCR autoantibodies (panel) across conditions.
Trials, interventions and tests
Commercial test availability
GPCR Functional Autoantibody Panel — specialty laboratory test. Functional autoantibody testing; not standard hospital lab menu.
Links are for reference only; availability, specimen requirements and coverage vary by location.
Related Autoimmune markers in ME/CFS
Full list: ME/CFS Biomarker Atlas.
Frequently asked questions
Is Anti-GPCR autoantibodies (panel) high or low in ME/CFS?
Elevated. Studies summarised in the OSMF atlas report higher Anti-GPCR autoantibodies (panel) in ME/CFS than in healthy controls; long COVID/post-acute COVID-19 vaccination syndrome overlap. Source: Maksoud et al. 2023.
What symptoms is Anti-GPCR autoantibodies (panel) associated with in ME/CFS?
The cited literature associates this marker with Dysautonomia. These are population-level associations and do not mean the marker causes the symptoms.
Which test measures Anti-GPCR autoantibodies (panel)?
It is measured as a blood test (serum / plasma / whole blood). Commercial laboratories such as CellTrend (specialty) list an orderable assay.
Is one abnormal Anti-GPCR autoantibodies (panel) result diagnostic of ME/CFS?
No. No single biomarker is diagnostic of ME/CFS. Anti-GPCR autoantibodies (panel) findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.
Is Anti-GPCR autoantibodies (panel) specific to ME/CFS?
No. The same marker is also reported in Long COVID, PACVS in this atlas, so it reflects shared biology (for example inflammation or vascular stress) rather than a condition-specific signature.
Cite this page
Subscribe on Substack
Last reviewed: 2026-06-29 · Page generated from me-cfs.json · Browse: ME/CFS atlas · Biomarker Index · All marker pages
Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.